Issue of Share Options / PDMR Shareholdings
Company issues 1,886,357 share options to directors, management and 64 other employees under ESOP.
- Share options issued 1,886,357
- Total share options outstanding post-grant 6,211,466
- Outstanding options as % of issued capital 7.32%
- Exercise price per share £0.002
- CEO options granted (Ryan Keeling) 271,688
- CFO options granted (Nick Roberts) 194,063
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
New York, Belfast and London, 23 July 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the issue of 1,886,357 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Performance Period |
|---|---|---|---|---|
| Ryan Keeling, CEO | 271,688 | 1,339,298 | 1.58% | 3 years from 22 July 2025 |
| Nick Roberts, CFO | 194,063 | 619,335 | 0.73% | 3 years from 22 July 2025 |
| Jordan Clark, CDO | 189,750 | 329,497 | 0.39% | 3 years from 22 July 2025 |
| Jillian Beggs, CCO and PDMR | 83,771 | 188,851 | 0.22% | 3 years from 22 July 2025 |
| Sandra Blake, CPO and PDMR | 86,250 | 162,586 | 0.19% | 3 years from 22 July 2025 |
| Susanne Munksted, CPMO and PDMR | 88,187 | 323,423 | 0.38% | 3 years from 22 July 2025 |
| Other employees (64 persons) | 972,648 | 3,248,476 | 3.83% | 3 years from 22 July 2025 |
For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.
The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.
The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 6,211,466 representing approximately 7.32% of its current issued share capital of 84,812,636.
| a. | Name | 1. Ryan Keeling | CEO |
| 2. Nick Roberts | CFO | ||
| 3. Jordan Clark | CDO | ||
| 4. Jillian Beggs | CCO | ||
| 5. Sandra Blake | CPO | ||
| 6. Susanne Munksted | CPMO | ||
| 2 | Reason for notification | ||
| a. | Position/Status | As above | |
| b. | Initial notification/ Amendment | Initial notification | |
| a. | Name | Diaceutics plc | |
| b. | LEI | 213800VEWQBB39ZB8J81 | |
| a. | Description of the financial instrument, type of instrument | Ordinary shares of 0.2p each | |
| b. | Identification Code | ISIN: GB00BJQTGV64 | |
| c. | Nature of the transaction | Grant of share options | |
| d. | Price(s) and volume(s) | Price(s) | Volume(s) |
| 1. | Exercise price of 0.2p per share | 271,688 | |
| 2. | Exercise price of 0.2p per share | 194,063 | |
| 3. | Exercise price of 0.2p per share | 189,750 | |
| 4. | Exercise price of 0.2p per share | 83,771 | |
| 5. | Exercise price of 0.2p per share | 86,250 | |
| 6. | Exercise price of 0.2p per share | 88,187 | |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.